20 stories about Earnings
אנדראס פיביג מנכ"ל IFF פרוטרום

IFF's Frutarom Dream Hits Reality, Hard

17.02.20|Sophie Shulman
A little over a year after IFF's $6.4 billion acquisition of Israel-based Frutarom, its annual results for 2019 fail to deliver desired boost in sales
קור שולץ מנכ"ל טבע 9.11.19

Teva’s Small Print Gives Rise to Optimism

13.02.20|Sophie Shulman
The improvement CEO Kåre Shultz promised is not immediately evident in the drugmaker’s forecast for 2020, but a closer look shows Teva’s new brand drugs are starting to live up to their promise
default image

Verint to Split Into Two Companies: Cyber and Customer Engagement

05.12.19|Micky Grunfeld
Verint has a market capitalization of $3.2 billion on Nasdaq; the company rose 6.88% in after-hours trading following the announcement
מימין שי וינינגר ו  דניאל שרייבר מייסדי Lemonade למונייד

Lemonade Releases Financial Data Following News of Shelved IPO

17.11.19|Hagar Ravet
The company reported annual recurring revenue of $104.4 million and a loss ratio of 78%
מטה חברת טבע תרופות

Teva Up 25% on NYSE Since Third Quarter Reports

17.11.19|Sophie Shulman
The Israeli drugmaker closed 8.74% up on Friday after a Cleveland County District judge reduced the fine placed on Johnson and Jonhson in Oklahoma by $107 million, citing a math error made in the original ruling
מיכה קאופמן מנכ"ל פייבר fiverr

Fiverr Raises 2019 Revenue Guidance on Third Quarter Reports

14.11.19|Tzally Greenberg
The company published its earning reports Wednesday, announcing revenues that surpassed market expectations and losses lower than the analyst consensus
וויוורק ירושלים WeWork 1

WeWork Continues Downward Spiral With $1.25 Billion in Losses for 3Q 2019

The New York Times and Bloomberg first reported the company has more than doubled its losses year-over-year
קור שולץ מנכ"ל טבע 9.11.19

Teva Is Pulling an Ace From its Sleeve in its Attempt to Reinvent Itself

11.11.19|Uri Tal-Tene
With one anti-cancer biosimilar launching this week and another expected to hit the market soon, Teva could be creating a new growth engine worth hundreds of millions of dollars a year
קור שולץ מנכ"ל טבע 9.11.19

Teva Announces $1.5 Billion Debt Tender Offer

10.11.19|Sophie Shulman
On Thursday, the Israeli drugmaker published its third quarter reports for 2019, reporting it had cut down its net debt to $25.7 billion
מטה חברת טבע תרופות

Despite Losses, Teva Pays Employee Bonuses for 2018

13.08.19|Hezi Sternlicht
Though Teva ended 2018 with a net loss of over $2.45 billion, the company awarded its employees with bonuses worth $390 million for the fiscal year’s results
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Beats Analysts on Second Quarter Operating Income, Revenues

The company also announced chief financial officer Michael McClellan will be stepping down after two years for personal reasons related to family
מימין מנכ"ל אנבידיה ג'נסן הואנג ומנכ"ל מלאנוקס איל וולדמן

Just Before Nvidia Merger, Mellanox Reports 132% Increase in Net Income for Q2 2019

28.07.19|Tzally Greenberg
The Israeli chipmaker ended the second quarter of 2019 with a GAAP net income of $38.4 million and an almost 16% increase in revenue
אתר טבע כפר סבא

Fitch Downgrades Teva, Keeps Outlook at Negative

10.06.19|Hezi Sternlicht
Fitch pins the downgrade on the drugmaker's slow revenue growth, persisting cost challenges and downward pressure on generic drug prices, and the company's legal trouble in the U.S.
מיכה קאופמן מנכ"ל פייבר fiverr

Fiverr Wants to Go Public According to a Post-IPO Valuation of $650 Million

03.06.19|Hagar Ravet and Sophie Shulman
The online gig marketplace is looking to raise $121 million in its initial public offering on NYSE, according to its new prospectus
המל"ט דומינייטור של אירונאוטיקס

Acquisition Approval Still Pending, Aeronautics Erases $23 Million Due to Accounting Mistake

29.05.19|Hezi Sternlicht
In April, Aeronautics’ board approved its sale to Israeli defense contractor Rafael according to a company valuation of $237 million
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva’s Copaxone Successors Are Still Far From Success

05.05.19|Hezi Sternlicht
Teva’s first quarter report for 2019, published Thursday, shows that while the drugmaker is progressing with its financial rehabilitation program, its net debt to EBITDA ratio is leaving the company in dangerous waters
מגזין מנהלים 25.12.17 אני לא מסתנוור גיל שוויד

Check Point’s First Quarter: Revenues Slightly Up, Profit Slightly Down

18.04.19|Tzally Greenberg and Micky Grunfeld
The Nasdaq-listed network and cloud security provider published its first-quarter report for 2019 Thursday
מנכ"ל טבע קאר שולץ קור שולץ קר שולץ מנכ"ל טבע פברואר 2018

Teva Execs Topped TASE's High Earners List for 2018

18.04.19|Gil Kalian
With nearly $34 million added to the bank, Teva’s CEO Kåre Schultz was the highest earning executive on the Tel Aviv Stock Exchange last year
איל וולדמן מלאנוקס במסיבת עיתונאים

Hot Off Acquisition Announcement, Mellanox Reports Record Revenues for 2019 Q1

17.04.19|Lilach Baumer
In March, Nvidia announced an agreement to buy the company for $6.9 billion, valuing it at $125 per share